BLINATUMOMAB

Kaynaklar:

1-Kantarjian, H. A. Stein, N. Gokbuget, et al. 2017. "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia." N Engl J Med 376(9):836-847. 

2- Topp MS, Z. Zimmerman, P. Cannell, et al. 2018. "Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab." Blood.

3-Topp MS, Gökbuget N, Zugmaier G, et al. . Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185-5187. 

4-Topp MS, Kufer P, Gökbuget N, et al. . Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498. 

5- Brüggemann M, Schrauder A, Raff T, et al. ; International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24(3):521-535.

6-Topp MS, Gökbuget N, Stein AS, et al. . Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.